Hospital
Southwest Mississippi Regional Medical Center
Southwest Mississippi Regional Medical Center was paid $2.57M by Medicaid between Jan 2018 and Nov 2024, across 62 billing codes. Its largest line is 99283, emergency room visit (moderate) — 32% of everything it billed.
33Billing provider infoSOUTHWEST MISSISSIPPI REGIONAL MEDICAL CENTER
MONTICELLO, MS 39654
MONTICELLO, MS 39654
33aNPI1932211851assigned 08/31/2006
33bProvider typeCritical Access Hospital
28Total paid$2.57M
24GClaims62,294
24DCodes billed62
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in Mississippi
Rank by total paid#25 of 32
Median peer was paid$3.94M
This provider vs. median0.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official ROWLEY, CHARLA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 8,681 | $385K | |
| 2019 | 7,302 | $367K | |
| 2020 | 4,863 | $230K | |
| 2021 | 8,307 | $366K | |
| 2022 | 10,823 | $443K | |
| 2023 | 12,314 | $428K | |
| 2024incomplete | 10,004 | $353K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 32% | 7,714 | 5,978 | $836K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 3,632 | 2,838 | $448K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.6% | 1,431 | 1,118 | $196K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 6.5% | 2,052 | 1,757 | $166K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 4.6% | 1,238 | 1,045 | $117K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 3.0% | 1,607 | 1,121 | $78K |
| 71045 | Radiologic examination, chest; single view | 2.6% | 2,198 | 1,860 | $68K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 2.6% | 1,812 | 1,246 | $68K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 2.6% | 2,158 | 1,819 | $67K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.6% | 696 | 563 | $66K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 2.5% | 2,450 | 2,054 | $65K |
| 70450 | Computed tomography, head or brain; without contrast material | 2.0% | 662 | 562 | $51K |
50 more codes
| 71046 | Radiologic examination, chest; 2 views | 2.0% | 1,227 | $51K |
| 80053 | Comprehensive metabolic panel | 1.8% | 5,644 | $46K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.4% | 1,230 | $37K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 6,356 | $33K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 1.1% | 1,221 | $28K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 1.1% | 154 | $28K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 868 | $20K |
| 83880 | <1% | 1,188 | $18K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 939 | $11K |
| 84484 | <1% | 1,449 | $9K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,101 | $9K |
| 81001 | <1% | 3,690 | $7K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 571 | $6K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 219 | $6K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 42 | $5K |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 28 | $4K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 757 | $4K |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 58 | $3K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 13 | $3K |
| 87186 | <1% | 474 | $3K | |
| 82553 | <1% | 349 | $2K | |
| 81025 | <1% | 317 | $2K | |
| 87634 | <1% | 35 | $2K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 54 | $1K |
| 80305 | <1% | 129 | $844.74 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 76 | $717.60 |
| 87088 | <1% | 144 | $708.44 | |
| 73610 | <1% | 13 | $707.72 | |
| 80061 | Lipid panel | <1% | 116 | $697.32 |
| Q3014 | Telehealth originating site facility fee | <1% | 27 | $603.44 |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 119 | $596.18 |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 122 | $555.32 |
| 87040 | <1% | 102 | $424.09 | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,032 | $369.77 |
| 82550 | <1% | 108 | $335.91 | |
| 83735 | <1% | 108 | $314.43 | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 804 | $299.72 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 666 | $296.64 |
| 86140 | <1% | 74 | $253.24 | |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 19 | $230.59 |
| 85027 | <1% | 65 | $188.81 | |
| 83605 | <1% | 111 | $180.56 | |
| 83690 | <1% | 36 | $173.49 | |
| 82948 | <1% | 67 | $156.92 | |
| 85651 | <1% | 49 | $143.20 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 438 | $112.51 |
| 84145 | <1% | 14 | $1.64 | |
| A9270 | Non-covered item or service | <1% | 193 | $0.32 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 0% | 12 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROWLEY, CHARLA (CEO)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.